[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586569":3},{"organization":4,"armGroups":7,"interventions":89,"overallOfficials":95,"centralContacts":135,"locations":140,"responsibleParty":358,"collaborators":95,"id":360,"slug":361,"hasResults":362,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":95,"eligibilityCriteria":366,"healthyVolunteers":362,"sex":367,"minAge":368,"maxAge":95,"enrollmentInfo":369,"targetDuration":95,"studyType":372,"phases":373,"briefSummary":375,"conditions":376,"keywords":391,"overallStatus":143,"whyStopped":95,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":412},{"fullName":5,"class":6},"TheRas, Inc., d\u002Fb\u002Fa BBOT (BridgeBio Oncology Therapeutics)","INDUSTRY",[8,14,19,25,31,36,40,44,49,55,59,62,65,68,71,74,77,80,83,86],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1a - Dose Escalation Monotherapy","EXPERIMENTAL","Participants enrolled in this cohort will receive BBO-11818 as monotherapy",[13],"Drug: BBO-11818",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 1b - Dose Escalation Combination Therapy (Pembrolizumab)","Participants enrolled in this cohort will receive BBO-11818 in combination with pembrolizumab infusion (IV)",[13,18],"Drug: Pembrolizumab",{"label":20,"type":10,"description":21,"interventionNames":22},"Cohort 1c - Dose Escalation Combination Therapy (Pembrolizumab + Cis\u002Fcarboplatin + Pemetrexed)","Participants enrolled in this cohort will receive BBO-11818 in combination with pembrolizumab infusion (IV), cis\u002Fcarboplatin infusion (IV), and pemetrexed infusion (IV)",[13,18,23,24],"Drug: Platinum chemotherapy (cisplatin or carboplatin)","Drug: Pemetrexed",{"label":26,"type":10,"description":27,"interventionNames":28},"Cohort 1d - Dose Escalation Combination Therapy (Cetuximab ± mFOLFOX6)","Participants enrolled in this cohort will receive BBO-11818 in combination with cetuximab infusion (IV) with or without mFOLFOX6 infusion (IV)",[13,29,30],"Drug: Cetuximab","Drug: mFOLFOX6",{"label":32,"type":10,"description":33,"interventionNames":34},"Cohort 1e - Dose Escalation Combination Therapy (BBO-10203 + mFOLFOX6)","Participants enrolled in this cohort will receive BBO-11818 in combination with BBO-10203 and mFOLFOX6 infusion (IV)",[13,30,35],"Drug: BBO-10203",{"label":37,"type":10,"description":38,"interventionNames":39},"Cohort 1f - Dose Escalation Combination Therapy (BBO-10203 + Cetuximab)","Participants enrolled in this cohort will receive BBO-11818 in combination with BBO-10203 and cetuximab infusion (IV)",[13,29,35],{"label":41,"type":10,"description":42,"interventionNames":43},"Cohort 1g - Dose Escalation Combination Therapy (Cetuximab)","Participants enrolled in this cohort will receive BBO-11818 in combination with cetuximab infusion (IV)",[13,29],{"label":45,"type":10,"description":46,"interventionNames":47},"Cohort 1h - Dose Escalation Combination Therapy (mFOLFIRINOX)","Participants enrolled in this cohort will receive BBO-11818 in combination with mFOLFIRINOX infusion (IV)",[13,48],"Drug: mFOLFIRINOX",{"label":50,"type":10,"description":51,"interventionNames":52},"Cohort 1i - Dose Escalation Combination Therapy (Gemcitabine + Nab-paclitaxel)","Participants enrolled in this cohort will receive BBO-11818 in combination with gemcitabine infusion (IV) and nab-paclitaxel infusion (IV)",[13,53,54],"Drug: Gemcitabine","Drug: Nab-paclitaxel",{"label":56,"type":10,"description":57,"interventionNames":58},"Cohort 1j - Dose Escalation Combination Therapy (BBO-10203)","Participants enrolled in this cohort will receive BBO-11818 in combination with BBO-10203",[13,35],{"label":60,"type":10,"description":11,"interventionNames":61},"Cohort 2a - Dose Expansion Monotherapy",[13],{"label":63,"type":10,"description":16,"interventionNames":64},"Cohort 2b - Dose Expansion Combination (Pembrolizumab)",[13,18],{"label":66,"type":10,"description":21,"interventionNames":67},"Cohort 2c - Dose Expansion Combination Therapy (Pembrolizumab + Cis\u002Fcarboplatin + Pemetrexed)",[13,18,23,24],{"label":69,"type":10,"description":27,"interventionNames":70},"Cohort 2d - Dose Expansion Combination Therapy (Cetuximab ± mFOLFOX6)",[13,29,30],{"label":72,"type":10,"description":33,"interventionNames":73},"Cohort 2e - Dose Expansion Combination Therapy (BBO-10203 + mFOLFOX6)",[13,30,35],{"label":75,"type":10,"description":38,"interventionNames":76},"Cohort 2f - Dose Expansion Combination Therapy (BBO-10203 + Cetuximab)",[13,29,35],{"label":78,"type":10,"description":42,"interventionNames":79},"Cohort 2g - Dose Expansion Combination Therapy (Cetuximab)",[13,29],{"label":81,"type":10,"description":46,"interventionNames":82},"Cohort 2h - Dose Expansion Combination Therapy (mFOLFIRINOX)",[13,48],{"label":84,"type":10,"description":51,"interventionNames":85},"Cohort 2i - Dose Expansion Combination Therapy (Gemcitabine + Nab-paclitaxel)",[13,53,54],{"label":87,"type":10,"description":57,"interventionNames":88},"Cohort 2j - Dose Expansion Combination Therapy (BBO-10203)",[13,35],[90,96,100,104,108,112,116,119,123,127,131],{"type":91,"name":92,"description":93,"armGroupLabels":94,"otherNames":95},"DRUG","BBO-11818","Participants will receive assigned dose of BBO-11818 orally (PO)",[9,15,20,26,32,37,41,45,50,56,60,63,66,69,72,75,78,81,84,87],null,{"type":91,"name":97,"description":98,"armGroupLabels":99,"otherNames":95},"Pembrolizumab","Patients will receive IV pembrolizumab",[15,20,63,66],{"type":91,"name":101,"description":102,"armGroupLabels":103,"otherNames":95},"Platinum chemotherapy (cisplatin or carboplatin)","Patients will receive IV platinum chemotherapy (cisplatin or carboplatin)",[20,66],{"type":91,"name":105,"description":106,"armGroupLabels":107,"otherNames":95},"Pemetrexed","Patients will receive IV pemetrexed",[20,66],{"type":91,"name":109,"description":110,"armGroupLabels":111,"otherNames":95},"Cetuximab","Patients will receive IV cetuximab",[26,37,41,69,75,78],{"type":91,"name":113,"description":114,"armGroupLabels":115,"otherNames":95},"mFOLFOX6","Patients may receive IV mFOLFOX6",[26,69],{"type":91,"name":113,"description":117,"armGroupLabels":118,"otherNames":95},"Patients will receive IV mFOLFOX6",[32,72],{"type":91,"name":120,"description":121,"armGroupLabels":122,"otherNames":95},"BBO-10203","Participants will receive BBO-10203 orally (PO)",[32,37,56,72,75,87],{"type":91,"name":124,"description":125,"armGroupLabels":126,"otherNames":95},"mFOLFIRINOX","Patients will receive IV mFOLFIRINOX",[45,81],{"type":91,"name":128,"description":129,"armGroupLabels":130,"otherNames":95},"Gemcitabine","Patients will receive IV gemcitabine",[50,84],{"type":91,"name":132,"description":133,"armGroupLabels":134,"otherNames":95},"Nab-paclitaxel","Patients will receive IV nab-paclitaxel",[50,84],[136],{"name":5,"role":137,"phone":138,"phoneExt":95,"email":139},"CONTACT","(650) 405-4770","tbbo11818-101ct.gov@bbotx.com",[141,158,170,182,194,207,220,233,246,258,267,280,293,305,317,330,343],{"facility":142,"status":143,"city":144,"state":145,"zip":146,"country":147,"countryCode":148,"cosmosGeoPoint":149,"geoPoint":154,"contacts":155},"The Angeles Clinic and Research Institute - West Los Angeles Office","RECRUITING","Los Angeles","California","90025","United States","US",{"type":150,"coordinates":151},"Point",[152,153],-118.24368,34.05223,{"lat":153,"lon":152},[156],{"name":95,"role":137,"phone":157,"phoneExt":95,"email":95},"310-582-7900",{"facility":159,"status":143,"city":160,"state":145,"zip":161,"country":147,"countryCode":148,"cosmosGeoPoint":162,"geoPoint":166,"contacts":167},"University of California Davis","Sacramento","95817",{"type":150,"coordinates":163},[164,165],-121.4944,38.58157,{"lat":165,"lon":164},[168],{"name":95,"role":137,"phone":169,"phoneExt":95,"email":95},"916-734-5959",{"facility":171,"status":143,"city":172,"state":145,"zip":173,"country":147,"countryCode":148,"cosmosGeoPoint":174,"geoPoint":178,"contacts":179},"University of California San Diego Moores Cancer Center","San Diego","92037",{"type":150,"coordinates":175},[176,177],-117.16472,32.71571,{"lat":177,"lon":176},[180],{"name":95,"role":137,"phone":181,"phoneExt":95,"email":95},"858-822-6100",{"facility":183,"status":143,"city":184,"state":145,"zip":185,"country":147,"countryCode":148,"cosmosGeoPoint":186,"geoPoint":190,"contacts":191},"University of California San Francisco Helen Diller Family Comprehensive Cancer Center","San Francisco","94158",{"type":150,"coordinates":187},[188,189],-122.41942,37.77493,{"lat":189,"lon":188},[192],{"name":95,"role":137,"phone":193,"phoneExt":95,"email":95},"415-885-7796",{"facility":195,"status":143,"city":196,"state":197,"zip":198,"country":147,"countryCode":148,"cosmosGeoPoint":199,"geoPoint":203,"contacts":204},"Yale University","New Haven","Connecticut","06510",{"type":150,"coordinates":200},[201,202],-72.92816,41.30815,{"lat":202,"lon":201},[205],{"name":95,"role":137,"phone":206,"phoneExt":95,"email":95},"203-200-2486",{"facility":208,"status":143,"city":209,"state":210,"zip":211,"country":147,"countryCode":148,"cosmosGeoPoint":212,"geoPoint":216,"contacts":217},"Moffitt Cancer Center","Tampa","Florida","33612",{"type":150,"coordinates":213},[214,215],-82.45843,27.94752,{"lat":215,"lon":214},[218],{"name":95,"role":137,"phone":219,"phoneExt":95,"email":95},"888-663-3488",{"facility":221,"status":143,"city":222,"state":223,"zip":224,"country":147,"countryCode":148,"cosmosGeoPoint":225,"geoPoint":229,"contacts":230},"OSF Healthcare Cancer Institute","Peoria","Illinois","61637",{"type":150,"coordinates":226},[227,228],-89.58899,40.69365,{"lat":228,"lon":227},[231],{"name":95,"role":137,"phone":232,"phoneExt":95,"email":95},"309-308-3800",{"facility":234,"status":143,"city":235,"state":236,"zip":237,"country":147,"countryCode":148,"cosmosGeoPoint":238,"geoPoint":242,"contacts":243},"Massachusetts General Hospital","Boston","Massachusetts","02114",{"type":150,"coordinates":239},[240,241],-71.05977,42.35843,{"lat":241,"lon":240},[244],{"name":95,"role":137,"phone":245,"phoneExt":95,"email":95},"617-724-4000",{"facility":247,"status":143,"city":248,"state":248,"zip":249,"country":147,"countryCode":148,"cosmosGeoPoint":250,"geoPoint":254,"contacts":255},"NYU Langone Health","New York","10016",{"type":150,"coordinates":251},[252,253],-74.00597,40.71427,{"lat":253,"lon":252},[256],{"name":95,"role":137,"phone":257,"phoneExt":95,"email":95},"646-929-7870",{"facility":259,"status":143,"city":248,"state":248,"zip":260,"country":147,"countryCode":148,"cosmosGeoPoint":261,"geoPoint":263,"contacts":264},"Columbia University Irving Medical Center","10032",{"type":150,"coordinates":262},[252,253],{"lat":253,"lon":252},[265],{"name":95,"role":137,"phone":266,"phoneExt":95,"email":95},"877-426-5637",{"facility":268,"status":143,"city":269,"state":270,"zip":271,"country":147,"countryCode":148,"cosmosGeoPoint":272,"geoPoint":276,"contacts":277},"Vanderbilt University Medical Center","Nashville","Tennessee","37232",{"type":150,"coordinates":273},[274,275],-86.78444,36.16589,{"lat":275,"lon":274},[278],{"name":95,"role":137,"phone":279,"phoneExt":95,"email":95},"615-936-8422",{"facility":281,"status":143,"city":282,"state":283,"zip":284,"country":147,"countryCode":148,"cosmosGeoPoint":285,"geoPoint":289,"contacts":290},"Sarah Cannon Research Institute at Mary Crowley","Dallas","Texas","75230",{"type":150,"coordinates":286},[287,288],-96.80667,32.78306,{"lat":288,"lon":287},[291],{"name":95,"role":137,"phone":292,"phoneExt":95,"email":95},"972-566-3000",{"facility":294,"status":143,"city":295,"state":283,"zip":296,"country":147,"countryCode":148,"cosmosGeoPoint":297,"geoPoint":301,"contacts":302},"The University of Texas MD Anderson Cancer Center","Houston","77030",{"type":150,"coordinates":298},[299,300],-95.36327,29.76328,{"lat":300,"lon":299},[303],{"name":95,"role":137,"phone":304,"phoneExt":95,"email":95},"877-632-6789",{"facility":306,"status":143,"city":307,"state":283,"zip":308,"country":147,"countryCode":148,"cosmosGeoPoint":309,"geoPoint":313,"contacts":314},"NEXT Oncology","San Antonio","78229",{"type":150,"coordinates":310},[311,312],-98.49363,29.42412,{"lat":312,"lon":311},[315],{"name":95,"role":137,"phone":316,"phoneExt":95,"email":95},"210-580-9500",{"facility":318,"status":143,"city":319,"state":320,"zip":321,"country":147,"countryCode":148,"cosmosGeoPoint":322,"geoPoint":326,"contacts":327},"Huntsman Cancer Institute","Salt Lake City","Utah","84112",{"type":150,"coordinates":323},[324,325],-111.89105,40.76078,{"lat":325,"lon":324},[328],{"name":95,"role":137,"phone":329,"phoneExt":95,"email":95},"801-587-7000",{"facility":331,"status":143,"city":332,"state":333,"zip":334,"country":147,"countryCode":148,"cosmosGeoPoint":335,"geoPoint":339,"contacts":340},"Fred Hutchinson Cancer Center","Seattle","Washington","98109",{"type":150,"coordinates":336},[337,338],-122.33207,47.60621,{"lat":338,"lon":337},[341],{"name":95,"role":137,"phone":342,"phoneExt":95,"email":95},"206-667-5000",{"facility":344,"status":143,"city":345,"state":346,"zip":347,"country":348,"countryCode":349,"cosmosGeoPoint":350,"geoPoint":354,"contacts":355},"Peter MacCallum Cancer Centre","Melbourne","Victoria","3000","Australia","AU",{"type":150,"coordinates":351},[352,353],144.96332,-37.814,{"lat":353,"lon":352},[356],{"name":95,"role":137,"phone":357,"phoneExt":95,"email":95},"03-8559-5000",{"type":359,"investigatorFullName":95,"investigatorTitle":95,"investigatorAffiliation":95,"oldNameTitle":95,"oldOrganization":95},"SPONSOR","100586569","phase-1-bbo-11818-in-adult-subjects-with-kras-mutant-cancer-100586569",false,"NCT06917079","BBO-11818 in Adult Subjects With KRAS Mutant Cancer","A Phase 1a\u002F1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers","Inclusion Criteria:\n\n* Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation\n* Measurable disease by RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1\n* Life expectancy \\>24 weeks\n* Adequate organ function\n\nExclusion Criteria:\n\n* Malignancy within the last 2 years as specified in the protocol\n* Untreated brain metastases\n\nOther inclusion\u002Fexclusion criteria are specified in the protocol.","ALL","18 Years",{"count":370,"type":371},665,"ESTIMATED","INTERVENTIONAL",[374],"PHASE1","A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.",[377,378,379,380,381,382,383,384,385,386,387,388,389,390],"Non-Small Cell Lung Cancer","NSCLC","PDAC - Pancreatic Ductal Adenocarcinoma","CRC (Colorectal Cancer)","Metastatic Non-Small Lung Cell Cancer","Metastatic Colorectal Cancer (CRC)","KRAS G12A","KRAS G12C","KRAS G12D","KRAS G12S","KRAS G12V","Metastatic Pancreatic Ductal Adenocarcinoma","Advanced Lung Carcinoma","Solid Tumor, Adult",[392,393,394,395,378,396,397,398,399,97,109,400,105,401,402,113,124,128,132],"BBOT","BridgeBio Oncology Therapeutics","Phase1","Phase 1a\u002F1b","CRC","PDAC","Metastatic Cancer","Advanced Cancer","Platinum Chemotherapy","KONQUER","KONQUER-101","2026-05-29",{"date":405,"type":406},"2026-06-02","ACTUAL",{"date":408,"type":406},"2025-03-31",{"date":410,"type":371},"2029-09",{"name":5,"class":6},17]